

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
14 December 2023 (14.12.2023)



(10) International Publication Number
WO 2023/235915 A1

(51) International Patent Classification:

C12N 15/113 (2010.01) A61P 25/00 (2006.01)

A61K 31/7088 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/AU2023/050486

Published:

- with international search report (Art. 21(3))
- with amended claims (Art. 19(1))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(22) International Filing Date:

05 June 2023 (05.06.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2022901557 07 June 2022 (07.06.2022) AU

2022902778 26 September 2022 (26.09.2022) AU

2022903040 17 October 2022 (17.10.2022) AU

(71) Applicant: **PYC THERAPEUTICS LIMITED**

[AU/AU]; 6 Verdun Street, Nedlands, Western Australia 6009 (AU).

(72) Inventors: **PITOUT, Ianthe**; c/o PYC Therapeutics Limited,

of 6 Verdun Street, Nedlands, Western Australia 6009 (AU).

SIMMONS, Rebecca; c/o PYC Therapeutics Limited,

of 6 Verdun Street, Nedlands, Western Australia 6009 (AU).

FLETCHER, Susan; c/o PYC Therapeutics Limited,

6 Verdun Street, Nedlands, Western Australia 6009 (AU).

(74) Agent: **FB RICE PTY LTD**; Level 33, 477 Collins St, Melbourne,

Victoria 3000 (AU).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: COMPOSITIONS AND METHODS FOR TREATMENT OF MONOGENIC NEURODEVELOPMENTAL DISORDER

(57) Abstract: Described herein are antisense oligonucleotides, vectors, and related compositions and methods for increasing endogenous expression of SHANK3 protein and uses thereof for conditions associated with SHANK3 haploinsufficiency such as Phelan-McDermid syndrome.



WO 2023/235915 A1